home / stock / vrtx / vrtx articles
Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (NASDAQ: CRSP) to Neutral from Overweight, noting that its sickle cell ...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 7.47% on an annualized basis producing an average annual...
CNBC's Jim Cramer has drawn investors' attention to Vertex Pharmaceuticals (NASDAQ: VRTX), a biotechnology company curr...
The Nasdaq 100 closed lower by over 50 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares,...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 8.49% on an annualized basis producing an average annual...
In the current market session, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) stock price is at $353.85, after a 0.12% decrease. However, over the past ...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.6% on an annualized basis producing an average annual ...
News, Short Squeeze, Breakout and More Instantly...
Vertex Pharmaceuticals Incorporated Company Name:
VRTX Stock Symbol:
NASDAQ Market:
Vertex Pharmaceuticals Incorporated Website:
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations Canada NewsWire -Approximately 200 people with certain rare CF mutations are now ...